| ○ |
|
小山 哲夫 |
筑波大学名誉教授
|
| 腎臓学 |
Koyama A, Yamagata K, Makino H, Arimura Y, Wada T, Nitta K, Nihei H, Muso E, Taguma Y, Shigematsu H, Sakai H, Tomino Y, Matsuo S
A nationwide survey of rapidly progressive glomerulonephritis in Japan: etiology, prognosis and treatment diversity. ; Japan RPGN Registry Group.
Clin Exp Nephrol. Dec;13(6):633-50, 2009
|
Koyama A, Fujita T, Gejyo F, Origasa H, Isono M, Kurumatani H, Okada K, Kanoh H, Kiriyama T, Yamada S.
Orally active prostacyclin analogue beraprost sodium in patients with chronic kidney disease: a randomized, double-blind, placebo-controlled, phase II dose finding trial.
BMC Nephrol. Oct 16;16:165, 2015
|
Hirayama K, Nagai M, Ebihara I, Shimohata H, Kobayashi M, Koyama A.
Serum ratio of soluble triggering receptor expressed on myeloid cells-1 to creatinine is a useful marker of infectious complications in myeloperoxidase-antineutrophil cytoplasmic antibody-associated renal vasculitis.
Nephrol Dial Transplant. Mar;26(3):868-74, 2011
|
|
| |
|
富野 康日己 |
医療法人社団松和会 理事長
|
| 腎臓内科学 |
| “How to treat patients with chronic kidney disease: With special focus on IgA nephropathy” Yasuhiko Tomino. Nephrology. 2018 Oct. 23; Vol.23 Suppl. 4 :76-79
|
| “Rac1 in podocytes promotes glomerular repair and limits the formation of sclerosis” Rin Asao, Takuto Seki, Miyuki Takagi, Hiroyuki Yamada, Fumiko Kodama, Yoshiko Hosoe-Nagai, Eriko Tanaka, Juan Alejandro Oliva Trejo, Kanae Yamamoto-Nonaka, Yu Sasaki, Teruo Hidaka, Takashi Ueno, Motoko Yanagita, Yusuke Suzuki, Yasuhiko Tomino, Katsuhiko Asanuma. Sci Rep. 2018 Mar 22; 8(1):5061.
|
| “Far-infrared therapy for secondary vascular access patency of hemodialysis patients” Hiroaki Io, Junichiro Nakata, Rumi Aoyama, Hiroyuki Inoshita, Takanori Nakano, Masanori Ishizaka, Mitsumine Fukui, Yasuhiko Tomino and Yusuke Suzuki. Renal Replacement Therapy (2019)5:31
DOI: 10/1186/s41100-019-0224-9
|
|
| |
|
下條文武 |
新潟大学名誉教授
|
| 内科・腎臓内科 |
|
Indoxyl Sulfate Promotes Macrophage IL-1β Production by Activating Aryl Hydrocarbon Receptor/NF-κ/MAPK Cascades, but the NLRP3 inflammasome Was Not Activated. Wakamatsu T, Yamamoto S, Ito T, Sato Y, Matsuo K, Takahashi Y, Yoshikatsu Kaneko Y, Shin Goto S, Kazama JJ , Gejyo F, Narita I. Toxins (Basel). 2018;10(3):124. doi:10.3390/ toxins 10030124.
|
|
Adsorption of Protein-Bound Uremic Toxins Through Direct Hemoperfusion With Hexadecyl-Immobilized Cellulose Beads in Patients Undergoing Hemodialysis.Yamamoto S, Sato M, Sato Y, Wakamatsu T , Takahashi Y, Iguchi A, Omori K, Yasushi Suzuki S, Ei I, Kaneko Y, Shin Goto , Kazama JJ, Gejyo F , Narita I. Artif Organs. 2018;42(1):88-93.
|
Orally active prostacyclin analogue beraprost sodium in patients with chronic kidney disease: a randomized, double-blind, placebo-controlled, phase II dose finding trial. Koyama A, Fujita T, Gejyo F, Origasa H, Isono M,Kurumatani H, Okada K, Kanoh H, Kiriyama T, Yamada S.
BMC Nephrol, 2015;16(!):165. DOI 10.1186/s12882-015-0130-5
|
|
| |
|
西﨑 祐史 |
順天堂大学 革新的医療技術開発研究センター 准教授 |
| 一般内科、臨床研究支援、医学教育 |
| Association between the ratio of serum n-3 to n-6 polyunsaturated fatty acids and acute coronary syndrome in non-obese patients with coronary risk factor: a multicenter cross-sectional study. Nishizaki Y, Shimada K, Tani S, Ogawa T, Ando J, Takahashi M, Yamamoto M, Shinozaki T, Miyazaki T, Miyauchi K, Nagao K, Hirayama A, Yoshimura M, Komuro I, Nagai R, Daida H. BMC Cardiovascular Disorders 20:160,2020. |
| Optimal Dose of n-3 Polyunsaturated Fatty Acids for Cardiovascular Event Prevention. Nishizaki Y and Daida H. Circulation Reports 2:260-264,2020.
|
| Awareness of Diagnostic Error among Japanese Residents: a Nationwide Study. Nishizaki Y, Shinozaki T, Kinoshita K, Shimizu T, Tokuda Y. J Gen Intern Med 33:445-448,2018.
|
|
